{ "schemaVersion": 2, "eyebrow": "Hematologic Oncology", "title": "Mantle Cell Lymphoma", "summary": "Confirm mantle cell lymphoma with tissue-based cyclin D1/CCND1 testing, distinguish its key diagnostic mimics, stage before treatment, and select induction intensity by fitness. Relapse management depends critically on prior BTK inhibitor exposure and eligibility for cellular therapy.", "seoDescription": "Point-of-care guide to mantle cell lymphoma diagnosis, pathology confirmation, frontline treatment intensity, maintenance, relapse therapy, and transplant decisions.", "clinicalQuestion": "How should physicians confirm, risk-stratify, and sequence treatment for newly diagnosed or relapsed mantle cell lymphoma?", "specialty": "Hematology-Oncology", "audience": "U.S. physicians and medical trainees", "tags": [ "mantle cell lymphoma", "MCL", "cyclin D1", "t(11;14)", "SOX11", "BTK inhibitor", "autologous stem-cell transplantation", "CAR T-cell therapy" ], "keyTakeaways": [ "Do not diagnose MCL from a CD5-positive B-cell flow cytometry phenotype alone; confirm with cyclin D1 and/or CCND1 rearrangement testing, with SOX11 particularly useful when cyclin D1 is negative. [15][16][17][18]", "CD23 and CD200 positivity favors SLL/CLL, whereas MCL is typically CD23-negative and FMC7-positive; focal cyclin D1 staining in CLL/SLL proliferation centers is not diagnostic of MCL. [17]", "For symptomatic advanced MCL, use rituximab-containing chemotherapy and match intensity to physiologic fitness; cytarabine-containing induction and high-dose consolidation are options for fit patients with chemosensitive disease. [22]", "After one prior line, BTK inhibition is an established relapse-directed option; pirtobrutinib has FDA approval in relapsed/refractory MCL after at least two prior lines including a covalent BTK inhibitor. [3][22]", "At relapse, obtain a current biopsy when feasible if morphology, growth kinetics, or treatment response raises concern for blastoid/pleomorphic transformation or an alternative lymphoma. [15][17]" ], "sections": [ { "id": "confirm-the-diagnosis", "eyebrow": "Pathology", "heading": "Confirm MCL before selecting treatment", "intro": "Resolve diagnostic mimics on excisional or core tissue rather than flow cytometry alone.", "paragraphs": [ "For a mature CD5-positive B-cell neoplasm, obtain tissue morphology, B-cell immunophenotyping, cyclin D1 immunohistochemistry, and CCND1 rearrangement testing by FISH when needed. The defining lesion is t(11;14)(q13;q32), juxtaposing CCND1 with the immunoglobulin heavy-chain locus and producing cyclin D1 overexpression. [16][17][20][21]", "Use SOX11 staining to support conventional MCL when cyclin D1 is negative or technically equivocal. SOX11 is positive in more than 90% of MCL, including cyclin D1-negative and blastoid cases; rare cyclin D1-negative tumors may instead show high cyclin D2 or cyclin D3 expression. [15][16][17]", "Review morphology and genetics with a hematopathologist when a cyclin D1-positive large B-cell process is encountered. Most DLBCL lacks CCND1/IGH rearrangement, cyclin D1, and SOX11, but rare DLBCL can express cyclin D1 without t(11;14) or SOX11 and can be mistaken for blastoid MCL. [15]" ], "bullets": [ "If CD23 and CD200 are positive, prioritize SLL/CLL in the differential; typical MCL is CD23-negative and FMC7-positive. [17]", "Do not call MCL from focal cyclin D1 positivity in CLL/SLL proliferation centers; uniform cyclin D1 and SOX11 expression in the B-cell population supports MCL. [17]", "If cyclin D1 is negative and FISH does not show t(11;14), evaluate SOX11 and consider CCND2/CCND3-rearranged MCL in the appropriate morphologic and immunophenotypic setting. [15][16][17]" ], "subsections": [], "table": { "caption": "Tissue-based distinctions among common CD5-positive B-cell lymphoma diagnostic considerations. [15][17]", "columns": [ "Diagnostic consideration", "Findings that support it", "Finding that changes the next step" ], "rows": [ [ "Mantle cell lymphoma", "Uniform cyclin D1 and SOX11 expression; FISH evidence of t(11;14)/CCND1 rearrangement supports MCL. [17][20]", "If cyclin D1 is negative, add SOX11 and assess for cyclin D2/CCND2 or cyclin D3/CCND3-associated disease. [15][16][17]" ], [ "SLL/CLL", "CD23 and CD200 positivity favors SLL/CLL over MCL. [17]", "Focal cyclin D1 positivity in proliferation centers does not establish MCL; pursue CCND1-rearrangement testing if morphology remains concerning. [17]" ], [ "DLBCL with cyclin D1 expression", "Large-cell morphology with absent CCND1/IGH translocation and absent SOX11 favors DLBCL rather than blastoid MCL. [15]", "Perform genetic and immunophenotypic correlation before assigning blastoid MCL and before using an MCL-directed treatment pathway. [15]" ] ] } }, { "id": "initial-staging-and-treatment-trigger", "eyebrow": "Initial Assessment", "heading": "Stage disease and decide whether treatment is required now", "intro": "Use formal lymphoma staging and response assessment before committing to an induction strategy.", "paragraphs": [ "At diagnosis, document measurable disease and establish a baseline for treatment response using the Lugano framework; clinical-trial criteria define measurable lymphoma as a lesion with longest diameter at least 1.5 cm, or bone marrow involvement detected by flow cytometry. [13][14] Obtain marrow assessment when marrow involvement will affect staging, response assessment, or trial eligibility.", "Treatment intensity should follow symptomatic burden, disease extent, response potential, and transplant fitness. For symptomatic advanced MCL, first-line therapy is chemotherapy combined with rituximab; the choice of intensity should account for patient fitness. [22]", "A patient with clinical instability from bulky disease, threatened end-organ function, cytopenias attributable to marrow infiltration, or rapidly progressive disease should proceed directly to hematology-oncology-directed treatment planning after diagnostic tissue is secured. Before cytotoxic therapy, define the intended pathway: lower-intensity chemoimmunotherapy, cytarabine-containing induction with planned high-dose consolidation, or a clinical trial." ], "bullets": [ "Record histologic subtype, including blastoid or pleomorphic morphology, because these can create diagnostic confusion with DLBCL and require expert pathology review. [15]", "Document prior anthracycline or bendamustine exposure, anti-CD20 exposure, and BTK inhibitor exposure at every relapse; these exposures determine eligibility and sequencing for later therapies and trials. [4][13][14]", "Use response to induction to determine candidacy for consolidation: chemosensitive MCL is defined as at least a partial response to induction chemotherapy in transplant guidance. [22]" ], "subsections": [], "table": { "caption": "Decision points before first-line MCL therapy. [22]", "columns": [ "Decision point", "Action", "Consequence" ], "rows": [ [ "Symptomatic advanced disease", "Start rituximab-containing chemotherapy and select intensity by fitness. [22]", "Avoid applying a single regimen intensity to all patients. [22]" ], [ "Fit patient considered for intensive treatment", "Consider cytarabine-containing immunochemotherapy. [22]", "If disease is chemosensitive, assess for high-dose chemotherapy and autologous transplantation consolidation. [22]" ], [ "Not fit for high-dose chemotherapy", "Use a non-transplant approach and reassess disease response after induction. [22]", "Maintenance rituximab may be considered after response to R-CHOP-based immunochemotherapy. [22]" ] ] } }, { "id": "frontline-treatment-and-consolidation", "eyebrow": "First-Line Therapy", "heading": "Select induction and consolidation by fitness and chemosensitivity", "intro": "Frontline therapy separates into transplant-eligible intensive and non-intensive pathways.", "paragraphs": [ "For fit patients with advanced MCL, cytarabine-containing immunochemotherapy is a recommended consideration. If induction produces at least a partial response and the patient remains fit, high-dose chemotherapy followed by autologous stem-cell transplantation is a consolidation option. [22] This pathway requires early transplant assessment during induction, rather than referral only after relapse.", "For patients not fit for high-dose chemotherapy, use rituximab-containing chemotherapy selected for tolerability and disease control. Bendamustine plus rituximab is among the most commonly used first-line MCL regimens. [2] In this population, maintenance rituximab every 2 months until progression may be considered after a response to R-CHOP-based immunochemotherapy. [22]", "For patients in remission after cytarabine-based induction and high-dose chemotherapy, maintenance rituximab every 2 months for 3 years may be considered. [22] Discuss the maintenance plan before consolidation, because the intended induction and consolidation pathway determines the applicable maintenance approach." ], "bullets": [ "Use transplant consolidation only after chemosensitive disease; at least a partial response to induction is the stated threshold. [22]", "Include rituximab in first-line chemotherapy for symptomatic advanced disease. [22]", "When intensive therapy is contemplated, confirm that the pathology is true MCL rather than cyclin D1-positive DLBCL before proceeding with an MCL-specific consolidation plan. [15]" ], "subsections": [], "table": { "caption": "Fitness-based frontline MCL pathways. [2][22]", "columns": [ "Clinical pathway", "Induction or consolidation decision", "Maintenance decision" ], "rows": [ [ "Fit, advanced, symptomatic MCL", "Consider cytarabine-containing immunochemotherapy; if at least partial response and transplant fit, consider high-dose chemotherapy with autologous stem-cell transplantation. [22]", "Consider rituximab every 2 months for 3 years after cytarabine-based induction and high-dose chemotherapy in remission. [22]" ], [ "Not fit for high-dose chemotherapy", "Use rituximab-containing chemotherapy matched to tolerability; bendamustine-rituximab is commonly used first line. [2][22]", "Consider rituximab every 2 months until progression after response to R-CHOP-based immunochemotherapy. [22]" ] ] } }, { "id": "relapsed-refractory-disease", "eyebrow": "Relapse", "heading": "Sequence relapse therapy by prior BTK inhibitor exposure", "intro": "At progression, reassess pathology, treatment history, performance status, and candidacy for cellular therapy.", "paragraphs": [ "At first relapse after one prior treatment line, BTK inhibition is a central treatment branch; NICE identifies zanubrutinib and ibrutinib as options for adults with relapsed or refractory MCL after one line of therapy. [22] Record whether a prior BTK inhibitor was covalent, whether progression occurred on treatment, and whether discontinuation was driven by intolerance, because these distinctions govern the relevance of noncovalent BTK inhibition and cellular therapy.", "For MCL that has progressed after a covalent BTK inhibitor, pirtobrutinib is a noncovalent BTK inhibitor with FDA approval for relapsed or refractory MCL after at least two prior lines of therapy, including a covalent BTK inhibitor. [3] This indication should not be extrapolated to BTK inhibitor-naive disease.", "Refer early for cellular therapy assessment in patients with multiply relapsed disease, particularly after prior chemotherapy, anti-CD20 therapy, and BTK inhibitor exposure. Trial and product-development populations for CAR T-cell approaches have commonly required prior anthracycline- or bendamustine-containing chemotherapy, anti-CD20 therapy, and BTK inhibitor therapy. [4][14] Use a current disease assessment to determine whether there is measurable disease and whether bridging treatment is required while cellular therapy is organized." ], "bullets": [ "Repeat biopsy when clinical behavior is discordant with the prior diagnosis, when large-cell transformation is suspected, or when a new tissue diagnosis could alter therapy. [15][17]", "Document prior covalent BTK inhibitor exposure before considering pirtobrutinib; it is part of the FDA-approved treatment setting. [3]", "Consider clinical trial enrollment throughout relapsed/refractory disease, particularly for patients with progression after BTK inhibition or limited durable standard options. [4][9][13][14]" ], "subsections": [], "table": { "caption": "Relapsed/refractory MCL treatment branching based on prior therapy. [3][22]", "columns": [ "Prior treatment state", "Next treatment branch", "Critical verification" ], "rows": [ [ "One prior line; relapsed or refractory", "Consider covalent BTK inhibitor therapy, including ibrutinib or zanubrutinib. [22]", "Confirm prior regimen and reassess tissue if phenotype or tempo has changed. [15][17]" ], [ "At least two prior lines including a covalent BTK inhibitor", "Pirtobrutinib is FDA approved for relapsed/refractory MCL in this setting. [3]", "Verify prior covalent BTK inhibitor exposure and current disease status. [3]" ], [ "Multiply relapsed after chemotherapy, anti-CD20 therapy, and BTK inhibition", "Assess promptly for CAR T-cell therapy or a clinical trial. [4][14]", "Establish measurable disease and current fitness while arranging referral. [13][14]" ] ] } }, { "id": "monitoring-and-reassessment", "eyebrow": "Follow-Up", "heading": "Use response status and changing disease biology to redirect care", "intro": "Response, relapse tempo, and new morphology should trigger a new treatment decision rather than automatic regimen reuse.", "paragraphs": [ "Apply Lugano-based response assessment after induction and at suspected progression; measurable lesions are defined in trial settings as at least 1.5 cm in longest diameter, with marrow involvement assessable by flow cytometry. [13][14] For transplant planning, distinguish complete response from partial response, but recognize that at least partial response establishes chemosensitivity for consolidation decisions. [22]", "After autologous transplantation, molecular relapse has been studied as a setting for pre-emptive rituximab, but this should be directed within an experienced MCL program rather than substituted for standard clinical and radiographic assessment. [23] In patients with recurrent disease, reassess both histology and the complete exposure sequence before selecting another line.", "A new aggressive clinical course or large-cell morphology should prompt renewed consideration of blastoid/pleomorphic MCL versus DLBCL. The distinction requires correlation of morphology, cyclin D1, SOX11, and CCND1/IGH rearrangement status because rare cyclin D1-positive DLBCL can mimic MCL. [15]" ], "bullets": [ "At each progression, update: biopsy result when obtained, measurable disease status, prior anti-CD20 therapy, chemotherapy class exposure, transplant history, and covalent BTK inhibitor exposure. [3][4][13][14]", "Use induction response—not baseline intent alone—to determine whether high-dose consolidation remains appropriate. [22]" ], "subsections": [], "table": { "caption": "Reassessment triggers that alter MCL management. [15][22][23]", "columns": [ "Trigger", "Required reassessment", "Management implication" ], "rows": [ [ "After induction therapy", "Determine response; at least partial response indicates chemosensitive disease. [22]", "Proceed with transplant consolidation assessment if otherwise fit. [22]" ], [ "Suspected molecular relapse after autologous transplantation", "Confirm the clinical context in an experienced MCL program. [23]", "Pre-emptive rituximab has been studied in this setting. [23]" ], [ "Rapid progression or new large-cell morphology", "Repeat tissue review with cyclin D1, SOX11, and CCND1/IGH testing as indicated. [15]", "Avoid assuming that all cyclin D1-positive large-cell lymphomas are blastoid MCL. [15]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1715519", "authors": "www.nejm.org", "host": "www.nejm.org" }, { "number": 2, "title": "Ibrutinib plus Bendamustine and Rituximab in Untreated ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2201817", "authors": "www.nejm.org", "host": "www.nejm.org" }, { "number": 3, "title": "Pirtobrutinib after a Covalent BTK Inhibitor in Chronic ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2300696", "authors": "www.nejm.org", "host": "www.nejm.org" }, { "number": 4, "title": "ONCO 25:S1", "detail": "academic.oup.com", "url": "https://academic.oup.com/oncolo/article-pdf/25/S1/S8/41923084/oncolo_25_s1_s8.pdf", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 5, "title": "NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ta677/documents/draft-scope-post-referral", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 6, "title": "A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE ( ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/65/NCT01996865/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 7, "title": "NCT00490529", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/29/NCT00490529/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 8, "title": "IMBRUVICA® (ibrutinib) PCYC-1143-CA Amendment 4 16 ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/74/NCT03112174/Prot_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 9, "title": "Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/64/NCT00703664/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 10, "title": "Study Details | NCT03964480 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT03964480", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov" }, { "number": 11, "title": "Non-Hodgkin's lymphoma", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng52/documents/draft-guideline", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 12, "title": "Study Details | NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT02858258", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov" }, { "number": 13, "title": "Study Details | NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT07259070", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov" }, { "number": 14, "title": "Study Details | NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT04767308", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov" }, { "number": 15, "title": "Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6547582", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 16, "title": "SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2770966", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 17, "title": "Mantle Cell Lymphoma - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK536985", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 18, "title": "SOX11 is a biomarker for cyclin D1-negative mantle cell ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4778333", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 19, "title": "SOX11 over-Expression Is a Specific Marker for Mantle Cell ...", "detail": "ashpublications.org", "url": "https://ashpublications.org/blood/article/120/21/2662/112820/SOX11-over-Expression-Is-a-Specific-Marker-for", "authors": "ashpublications.org", "host": "ashpublications.org" }, { "number": 20, "title": "Mantle cell lymphoma - PMC - NIH", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2770958", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 21, "title": "The pathologic diagnosis of mantle cell lymphoma", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/34114641", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Recommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng52/chapter/recommendations", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 23, "title": "Non-Hodgkin's lymphoma: diagnosis and management", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng52/evidence/appendices-ik-search-strategies-review-protocols-and-excluded-health-economic-papers-pdf-2551524593", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 24, "title": "Cytarabine (Conventional) | Drug Lookup | Pediatric Care ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatriccare/drug-monograph/18/5260/Cytarabine-Conventional", "authors": "publications.aap.org", "host": "publications.aap.org" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1715519", "authors": "www.nejm.org", "host": "www.nejm.org", "snippet": "by CS Tam · 2018 · Cited by 510 — Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma.", "score": 0.6301622 }, { "number": 2, "title": "Ibrutinib plus Bendamustine and Rituximab in Untreated ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2201817", "authors": "www.nejm.org", "host": "www.nejm.org", "snippet": "by ML Wang · 2022 · Cited by 285 — Combination therapy with bendamustine and rituximab has become one of the most-used first-line regimens for mantle-cell lymphoma, given evidence", "score": 0.41151342 }, { "number": 3, "title": "Pirtobrutinib after a Covalent BTK Inhibitor in Chronic ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2300696", "authors": "www.nejm.org", "host": "www.nejm.org", "snippet": "by AR Mato · 2023 · Cited by 298 — Pirtobrutinib recently received Food and Drug Administration approval for the treatment of relapsed or refractory mantle-cell lymphoma after two", "score": 0.40359092 }, { "number": 4, "title": "ONCO 25:S1", "detail": "academic.oup.com", "url": "https://academic.oup.com/oncolo/article-pdf/25/S1/S8/41923084/oncolo_25_s1_s8.pdf", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Combination time-limited therapy with obinutuzumab, an anti-CD20 antibody, and venetoclax, a B-cell lymphoma. 2 (BCL2) inhibitor, has emerged as a standard", "score": 0.18550447 }, { "number": 5, "title": "NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ta677/documents/draft-scope-post-referral", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "Statistics, England, 2017. Office of National Statistics. Accessed September 2019 2. Mantle cell lymphoma. Cancer Research UK (using data from the Office for National Statistics and the regional cancer registries in Wales, Scotland and Northern Ireland using the latest data for 2017). Accessed Septe", "score": 0.7237202 }, { "number": 6, "title": "A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE ( ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/65/NCT01996865/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "1.2.1 Therapy in Relapsed/Refractory Mantle Cell Lymphoma For the treatment of patients with newly diagnosed MCL, the National Comprehensive Cancer Network (NCCN) NHL guidelines and the recent European Society for Medical Oncology (ESMO) consensus suggest that rituximab should be part of any inducti", "score": 0.7014069 }, { "number": 7, "title": "NCT00490529", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/29/NCT00490529/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol, 1992. 16(7): p. 637-40. 2. Velders, G.A., et al., Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol, 1996. 14(4): p. 1269-74. 3. Armitage, J.O. and D.D. Weisenburger, New approach to cla", "score": 0.65940565 }, { "number": 8, "title": "IMBRUVICA® (ibrutinib) PCYC-1143-CA Amendment 4 16 ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/74/NCT03112174/Prot_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604-11. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refra", "score": 0.6479992 }, { "number": 9, "title": "Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/64/NCT00703664/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "the National Comprehensive Cancer Network (NCCN) Physician Guidelines (v2.2007): Mantle cell lymphoma has the worst characteristics of both indolent and aggressive non-Hodgkin's lymphomas. Like many of the more common indolent lymphoid neoplasms, mantle cell lymphoma appears to be incurable with con", "score": 0.62742686 }, { "number": 10, "title": "Study Details | NCT03964480 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT03964480", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov", "snippet": "Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell", "score": 0.5835125 }, { "number": 11, "title": "Non-Hodgkin's lymphoma", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng52/documents/draft-guideline", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "and there will be a minor change in practice through the reinforcement of current best practice for the treatment of patients with non-gastric MALT lymphoma. The GC noted that the recommendations about the use of antibiotic therapy in patients with gastric MALT lymphoma negative for helicobacter pyl", "score": 0.53269315 }, { "number": 12, "title": "Study Details | NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT02858258", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov", "snippet": "Human subjects protection review board A group of people who review, approve, and monitor the clinical study's protocol. Their role is to protect the rights and welfare of people participating in a study (referred to as human research subjects), such as reviewing the informed consent form. The group", "score": 0.40161797 }, { "number": 13, "title": "Study Details | NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT07259070", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov", "snippet": "1.Relapsed and refractory (R/R) BAFF-R-positive B-cell lymphoma:The diagnosis of B-cell lymphoma must be confirmed in accordance with the NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas (Version 1.2020) (NCCN: National Comprehensive Cancer Network).The expression of BAFF-R on tumor c", "score": 0.23173632 }, { "number": 14, "title": "Study Details | NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT04767308", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov", "snippet": "1. Chronic lymphocytic leukemia/small lymphocytic lymphoma: any BTK inhibitor have been given for at least 6 months and the treatment has failed (SD or PD).\n2. Mantle cell lymphoma (MCL): patients with MCL must have relapsed/refractory diseases after receiving at least one treatment regimen. Pre", "score": 0.22589478 }, { "number": 15, "title": "Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6547582", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "t(11;14)(13;q23) translocation between IgH and CCND1 is the hallmark of mantle cell lymphoma (MCL). cyclin D1 expression due to t (11;14, 13;q23) translocation between IgH and CCND1 is present in > 95% of cases including the minority of CD5 negative MCL. Variant CCND1 translocations do exist. In cas", "score": 0.7760977 }, { "number": 16, "title": "SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2770966", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "These results prompted us to investigate SOX11 expression in our cyclin D1-negative MCL. Interestingly, all of them showed strong SOX11 nuclear protein expression indicating that this may indeed be a useful marker to identify these tumors. Ek e _t al_.16 included a case of apparently cyclin D1-negat", "score": 0.7613083 }, { "number": 17, "title": "Mantle Cell Lymphoma - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK536985", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "The differential diagnosis primarily includes SLL/CLL and DLBCL. Both SLL/CLL and mantle cell lymphoma are CD5-positive, mature B-cell lymphomas and may be difficult to distinguish by flow cytometry alone. When there is positivity for CD200 and CD23, the diagnosis is most likely SLL/CLL. Mantle cell", "score": 0.7279179 }, { "number": 18, "title": "SOX11 is a biomarker for cyclin D1-negative mantle cell ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4778333", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "by R Narurkar · 2016 · Cited by 48 — Cyclin D1 (CCND1) protein overexpression and/or the t(11;14)(q13;q32) translocation are the pathognomonic hallmarks of mantle cell lymphoma (MCL).", "score": 0.7144891 }, { "number": 19, "title": "SOX11 over-Expression Is a Specific Marker for Mantle Cell ...", "detail": "ashpublications.org", "url": "https://ashpublications.org/blood/article/120/21/2662/112820/SOX11-over-Expression-Is-a-Specific-Marker-for", "authors": "ashpublications.org", "host": "ashpublications.org", "snippet": "SOX11 over-Expression Is a Specific Marker for Mantle Cell Lymphoma and Correlates with t(11;14) Translocation, CCND1 Expression, and an Adverse Prognosis.", "score": 0.70726365 }, { "number": 20, "title": "Mantle cell lymphoma - PMC - NIH", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2770958", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "by SA Pileri · 2009 · Cited by 129 — cyclin D1, t(11;14)(q13;q32) The t(11;14)(q13;q32) translocation is regarded as the primary genetic event in MCL.7,12. Immunophenotype The t(11;14)(q13;q32)", "score": 0.7062922 }, { "number": 21, "title": "The pathologic diagnosis of mantle cell lymphoma", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/34114641", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov", "snippet": "by S Li · 2021 · Cited by 21 — Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and", "score": 0.69274646 }, { "number": 22, "title": "Recommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng52/chapter/recommendations", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "with chemosensitive mantle cell lymphoma (that is, there has been at least a partial response to induction chemotherapy) and\n\nwho are fit enough for transplantation.\n\n#### Maintenance strategies\n\n##### 1.5.7\n\nConsider maintenance rituximab, every 2 months until disease progression, for people with n", "score": 0.6737291 }, { "number": 23, "title": "Non-Hodgkin's lymphoma: diagnosis and management", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng52/evidence/appendices-ik-search-strategies-review-protocols-and-excluded-health-economic-papers-pdf-2551524593", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "years and older) who have responded to induction Autologous transplantation Allogeneic/(Allogenic/ Each other No transplantation 1. Overall survival 2. Disease free survival Non-Hodgkin’s lymphoma: diagnosis and management Appendices I - K Page 105 therapy for Mantle-cell lymphoma. Subgroups:  Mant", "score": 0.6337056 }, { "number": 24, "title": "Cytarabine (Conventional) | Drug Lookup | Pediatric Care ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatriccare/drug-monograph/18/5260/Cytarabine-Conventional", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "... Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years", "score": 0.54608524 } ], "publishedAt": "2026-08-21T02:16:05.430197+00:00", "updatedAt": "2026-08-21T02:16:05.430197+00:00", "readingMinutes": 6, "slug": "mantle-cell-lymphoma" }